ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "49633975-0791-4b55-bd7e-3a0fac1f54b1"}, "_deposit": {"id": "2012460", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2012460"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02012460", "sets": ["1642838338003", "1642838407795"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Shiohama, Yasuo", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Naito, Tadasuke", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Matsuzaki, Toshio", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Tanaka, Reiko", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Tomoyose, Takeaki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Takashima, Hiroshi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Fukushima, Takuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Tanaka, Yuetsu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Saito, Mineki", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "en", "subitem_1522651041219": "Creative Commons Attribution 4.0"}, {"subitem_1522650717957": "en", "subitem_1522650727486": "https://creativecommons.org/licenses/by/4.0/", "subitem_1522651041219": "https://creativecommons.org/licenses/by/4.0/"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "HTLV-1"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "NY-ESO-1"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "ATL"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "HAM/TSP"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Monoclonal antibody"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "ELISA"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "Background:Detection of specific immune responses against cancer/testis antigen NY-ESO-1 was recently reported in patients with adult T-cell leukemia/lymphoma (ATL) and human T-cell leukemia virus type 1 (HTLV-1)-infected asymptomatic carriers (ACs). However, the relationship of the responses with the HTLV-1 proviral load (PVL) and the levels of viral gene expression remain unclear. Findings:We measured plasma levels of autoantibodies to NY-ESO-1 immunogenic tumor antigen in HTLV-1-infected individuals with different clinical status, and in healthy controls. Data were compared to tax and HBZ mRNA levels, and PVL. Plasma anti-NY-ESO-1 antibody was detectable in 13.7% (7/51) of ACs, 29.2% (38/130) of patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), and 18.9% (10/53) of patients with ATL. Anti-NY-ESO-1 plasma levels were significantly higher in patients with HAM/TSP than in patients with ATL or ACs. Anti-NY-ESO-1 levels were not associated with PVL or the expression levels of tax and HBZ mRNA among HTLV-1-infected individuals, regardless of clinical status. Conclusions:The present results indicate the strong humoral immune response against NY-ESO-1 in natural HTLV-1 infection, irrespective of the clinical status. The higher immunoreactivity against NY-ESO-1 is not simply associated with the levels of both HTLV-1 gene expression and the number of infected cells in vivo. Rather, it might reflect chronic and generalized immune activation in infected individuals.", "subitem_description_type": "Other"}, {"subitem_description": "\u8ad6\u6587", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "en", "subitem_1522300316516": "BioMed Central"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "eng"}]}, "item_1617186783814": {"attribute_name": "Identifier", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/20.500.12000/46075"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1743-422X"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "en", "subitem_1522650091861": "Virology Journal"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicVolumeNumber": "14"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617353299429": {"attribute_name": "Relation", "attribute_value_mlt": [{"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "https://doi.org/10.1186/s12985-017-0802-9"}}, {"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "https://doi.org/10.1186/s12985-017-0802-9"}}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "s12985-017-0802-9.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2012460/files/s12985-017-0802-9.pdf"}, "version_id": "07871f17-25af-4d15-af04-b5fc41d09d4c"}]}, "item_title": "Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status", "item_type_id": "15", "owner": "1", "path": ["1642838338003", "1642838407795"], "permalink_uri": "http://hdl.handle.net/20.500.12000/46075", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2020-06-08"}, "publish_date": "2020-06-08", "publish_status": "0", "recid": "2012460", "relation": {}, "relation_version_is_last": true, "title": ["Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. その他
  1. 部局別インデックス
  2. 医学部

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status

http://hdl.handle.net/20.500.12000/46075
http://hdl.handle.net/20.500.12000/46075
621db360-1f3c-497e-92f3-9678802fee65
名前 / ファイル ライセンス アクション
s12985-017-0802-9.pdf s12985-017-0802-9.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2020-06-08
タイトル
タイトル Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
言語 en
作成者 Shiohama, Yasuo

× Shiohama, Yasuo

en Shiohama, Yasuo

Naito, Tadasuke

× Naito, Tadasuke

en Naito, Tadasuke

Matsuzaki, Toshio

× Matsuzaki, Toshio

en Matsuzaki, Toshio

Tanaka, Reiko

× Tanaka, Reiko

en Tanaka, Reiko

Tomoyose, Takeaki

× Tomoyose, Takeaki

en Tomoyose, Takeaki

Takashima, Hiroshi

× Takashima, Hiroshi

en Takashima, Hiroshi

Fukushima, Takuya

× Fukushima, Takuya

en Fukushima, Takuya

Tanaka, Yuetsu

× Tanaka, Yuetsu

en Tanaka, Yuetsu

Saito, Mineki

× Saito, Mineki

en Saito, Mineki

アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 en
権利情報 Creative Commons Attribution 4.0
言語 en
権利情報Resource https://creativecommons.org/licenses/by/4.0/
権利情報 https://creativecommons.org/licenses/by/4.0/
主題
言語 en
主題Scheme Other
主題 HTLV-1
言語 en
主題Scheme Other
主題 NY-ESO-1
言語 en
主題Scheme Other
主題 ATL
言語 en
主題Scheme Other
主題 HAM/TSP
言語 en
主題Scheme Other
主題 Monoclonal antibody
言語 en
主題Scheme Other
主題 ELISA
内容記述
内容記述タイプ Other
内容記述 Background:Detection of specific immune responses against cancer/testis antigen NY-ESO-1 was recently reported in patients with adult T-cell leukemia/lymphoma (ATL) and human T-cell leukemia virus type 1 (HTLV-1)-infected asymptomatic carriers (ACs). However, the relationship of the responses with the HTLV-1 proviral load (PVL) and the levels of viral gene expression remain unclear. Findings:We measured plasma levels of autoantibodies to NY-ESO-1 immunogenic tumor antigen in HTLV-1-infected individuals with different clinical status, and in healthy controls. Data were compared to tax and HBZ mRNA levels, and PVL. Plasma anti-NY-ESO-1 antibody was detectable in 13.7% (7/51) of ACs, 29.2% (38/130) of patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), and 18.9% (10/53) of patients with ATL. Anti-NY-ESO-1 plasma levels were significantly higher in patients with HAM/TSP than in patients with ATL or ACs. Anti-NY-ESO-1 levels were not associated with PVL or the expression levels of tax and HBZ mRNA among HTLV-1-infected individuals, regardless of clinical status. Conclusions:The present results indicate the strong humoral immune response against NY-ESO-1 in natural HTLV-1 infection, irrespective of the clinical status. The higher immunoreactivity against NY-ESO-1 is not simply associated with the levels of both HTLV-1 gene expression and the number of infected cells in vivo. Rather, it might reflect chronic and generalized immune activation in infected individuals.
内容記述タイプ Other
内容記述 論文
出版者
言語 en
出版者 BioMed Central
言語
言語 eng
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
識別子
識別子 http://hdl.handle.net/20.500.12000/46075
識別子タイプ HDL
関連情報
関連識別子
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s12985-017-0802-9
関連識別子
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s12985-017-0802-9
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1743-422X
収録物名
言語 en
収録物名 Virology Journal
書誌情報
巻 14
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-02 02:10:15.962569
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON

確認


Powered by WEKO3


Powered by WEKO3